<DOC>
	<DOCNO>NCT03036124</DOCNO>
	<brief_summary>The purpose study evaluate effect dapagliflozin incidence worsen heart failure cardiovascular death patient chronic heart failure reduce ejection fraction .</brief_summary>
	<brief_title>Study Evaluate Effect Dapagliflozin Incidence Worsening Heart Failure Cardiovascular Death Patients With Chronic Heart Failure</brief_title>
	<detailed_description>This international , multicentre , parallel group , event-driven , randomize , double-blind , placebo-controlled study patient chronic heart failure reduce ejection fraction ( HFrEF ) , evaluate effect dapagliflozin versus placebo , give daily addition background regional standard care therapy , prevention cardiovascular ( CV ) death reduction heart failure ( HF ) event .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Provision sign informed consent prior study specific procedure Male female , age ≥18 year Established documented diagnosis symptomatic HFrEF ( NYHA functional class IIIV ) , present least 2 month LVEF≤40 % NTproBNP ≥600 pg/ml Patients receive background standard care HFrEF eGFR ≥30 ml/min/1.73 m2 ( CKDEPI formula ) enrolment ( visit 1 ) Receiving therapy SGLT2 inhibitor within 8 week prior enrolment previous intolerance SGLT2 inhibitor Type 1 diabetes mellitus Symptomatic hypotension systolic BP &lt; 95 mmHg Current acute decompensated HF hospitalization due decompensated HF &lt; 4 week prior enrolment MI , unstable angina , stroke transient ischemic attack within 12 week prior enrolment Coronary revascularization ( percutaneous coronary intervention coronary artery bypass graft ) valvular repair/replacement within 12 week prior enrolment plan undergo operation randomization Implantation cardiac CRT within 12 week prior enrolment intent implant CRT device Previous cardiac transplantation implantation ventricular assistance device similar device , implantation expect randomization HF due restrictive cardiomyopathy , active myocarditis , constrictive pericarditis , hypertrophic ( obstructive ) cardiomyopathy uncorrected primary valvular disease Symptomatic bradycardia second third degree heart block without pacemaker Severe ( eGFR &lt; 30 mL/min/1.73 m2 CKDEPI ) , unstable rapidly progress renal disease time randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HFrEF</keyword>
	<keyword>Heart Failure ( HF )</keyword>
	<keyword>Cardiovascular Events ( CV )</keyword>
	<keyword>Phase III outcome trial</keyword>
</DOC>